<DOC>
	<DOC>NCT00098345</DOC>
	<brief_summary>The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.</brief_summary>
	<brief_title>Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Locally advanced or hereditary medullary thyroid cancer Signed informed consent One or more measurable lesions Brain metastases or spinal cord compression Specific laboratory ranges Specific heart problems Prior chemotherapy and/or radiation therapy Participation in other trials within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Caprelsa (vandetanib)</keyword>
	<keyword>ZD6474</keyword>
</DOC>